{"id":2380,"date":"2025-01-10T11:32:46","date_gmt":"2025-01-10T08:32:46","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2380"},"modified":"2025-03-27T16:49:38","modified_gmt":"2025-03-27T13:49:38","slug":"nippon-shinyaku-releases-first-clinical-trial-first-in-human-of-brogidirsen-ns-089-ncnp-02-for-the-treatment-of-duchenne","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/nippon-shinyaku-releases-first-clinical-trial-first-in-human-of-brogidirsen-ns-089-ncnp-02-for-the-treatment-of-duchenne\/","title":{"rendered":"Nippon Shinyaku publie le premier essai clinique (le premier chez l&#039;homme) du Brogidirsen NS-089\/NCNP-02 pour le traitement de la maladie de Duchenne"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Le Centre national de neurologie et de psychiatrie a annonc\u00e9 la publication d&#039;un article de recherche dans Cell Reports Medicine d\u00e9taillant les r\u00e9sultats d&#039;un essai clinique initi\u00e9 par des chercheurs pour le NS-089\/NCNP-02, connu sous le nom de \u00ab brogidirsen \u00bb. Ce traitement innovant pour la dystrophie musculaire de Duchenne (DMD), d\u00e9velopp\u00e9 conjointement avec Nippon Shinyaku Co., Ltd., repr\u00e9sente une avanc\u00e9e significative dans le traitement du saut d&#039;exon 44.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>Table des mati\u00e8res<\/h2><nav><ul><li><a href=\"#key-findings-from-brogidirsen-include\">R\u00e9sultats de l&#039;essai clinique Brogidirsen<\/a><\/li><li><a href=\"#what-is-brogidirsen\">Qu&#039;est-ce que Brogidirsen ?<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"key-findings-from-brogidirsen-include\">R\u00e9sultats de l&#039;essai clinique Brogidirsen<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Le brogidirsen montre une restauration dose-d\u00e9pendante de la dystrophine dans les essais sur les patients atteints de DMD.<\/li>\n\n\n\n<li>Le brogidirsen \u00e0 haute dose a atteint 24,47% de niveau normal de dystrophine dans la cohorte DMD.<\/li>\n\n\n\n<li>L\u2019essai a d\u00e9montr\u00e9 des b\u00e9n\u00e9fices th\u00e9rapeutiques avec une fonction motrice stable ou am\u00e9lior\u00e9e et un profil de s\u00e9curit\u00e9 favorable sans \u00e9v\u00e9nements ind\u00e9sirables graves.<\/li>\n\n\n\n<li>Des biomarqueurs s\u00e9riques pour la DMD ont \u00e9t\u00e9 identifi\u00e9s, notamment PADI2, TTN, MYOM2 et MYLPF.<\/li>\n\n\n\n<li>Le brogidirsen a montr\u00e9 une grande efficacit\u00e9 dans les cellules d\u00e9riv\u00e9es de l&#039;urine DMD, soutenant les essais sur l&#039;homme.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-brogidirsen\">Qu&#039;est-ce que Brogidirsen ?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Le Brogidirsen (NS-089\/NCNP-02) est un m\u00e9dicament \u00e0 base d&#039;acide nucl\u00e9ique co-d\u00e9couvert par Nippon Shinyaku et NCNP, et devrait \u00eatre un m\u00e9dicament th\u00e9rapeutique pour les patients atteints de DMD pr\u00e9sentant des mutations du g\u00e8ne de la dystrophine susceptibles de sauter l&#039;exon 44.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Apprendre encore plus:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/fr\/upcoming-exon-44-skipping-therapies-for-dmd\/\" data-type=\"post\" data-id=\"2811\">Th\u00e9rapies par saut d&#039;exon 44 \u00e0 venir pour le traitement de la dystrophie musculaire de Duchenne<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>The National Center of Neurology and Psychiatry is announced the publication of a research paper in Cell Reports Medicine detailing the results of an investigator-initiated trial for NS-089\/NCNP-02, known as &#8220;brogidirsen.&#8221; This innovative treatment for Duchenne muscular dystrophy (DMD), jointly developed with Nippon Shinyaku Co., Ltd., represents a significant advancement in exon 44 skipping therapy. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2383,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[138,137,141,127,77,142,136,139,140],"class_list":["post-2380","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-brogidirsen","tag-clinical-trial","tag-exon-44","tag-exon-44-skipping","tag-exon-skipping","tag-japan","tag-nippon-shinyaku","tag-ns-089","tag-ns-089-ncnp-02"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/2380","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=2380"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/2380\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/2383"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=2380"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=2380"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=2380"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}